Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.20 -1.36%

-$0.06 today

Market cap
$224.30M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.45M

Average 0.49M

BCYC Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Bicycle Therapeutics plcNASDAQ: BCYC

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -7394.5%

Operating margin was -7394.5% in Q1 FY2026, down 6690.8 pp from a year earlier. On a trailing-twelve-month basis it was -381.8%, up 583.8 pp year over year. Over 3 fiscal years it widened by 465.3 pp.

Context

  • Operating margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 7 analysts of -416.6% for the fiscal year ending Dec 2026, down from -341.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-7394.5%-7343.1 pp QoQ
Last fiscal yearDec 2025
-341.3%+253.7 pp YoY
LTMMar 2026
-381.8%+583.8 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6690.8 pp+2012.6 pp+8703.4 pp
1 year+253.7 pp-75.3 pp-329.0 pp
3 years+465.3 pp-942.3 pp-1407.6 pp
5 years+266.4 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-341.3%
Year-over-year change
+253.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 operating margin of -381.8% is the 6th highest of the 7 companies compared; the peer median is -176.6%.
  • Its year-over-year change of +583.8 pp is the 2nd highest of 5, against a peer median of +274.8 pp.
  • Over three fiscal years its change of +465.3 pp compares with a peer median of +1627.4 pp.
BCYC Competitors Peer median
Operating Margin for BCYC and competitors
Company Period LTM level YoY 3-year change
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026-34.8% +533.8 pp+72391.0 pp
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025-120.8% ——
ADCTADC Therapeutics S.A.LTM Mar 2026-149.6% +15.9 pp-74.5 pp
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-203.5% +883822.6 pp+3329.3 pp
PRTAProthena Corporation plcLTM Mar 2026-217.9% -117.5 pp-1661.8 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-381.8% +583.8 pp+465.3 pp
OMEROmeros CorporationLTM Mar 2026-1063.9% ——
FULCFulcrum Therapeutics, Inc.FY2025— ——
CMPXCompass Therapeutics, Inc.FY2025— ——
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding BCYC) -176.6%+274.8 pp+1627.4 pp

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue11.7M14.46M26.98M35.28M72.59M
Cost of Revenue00156.5M172.97M0
Gross Profit11.7M14.46M(129.52M)(137.69M)72.59M
Gross Margin100.0%100.0%-480.1%-390.3%100.0%
Research & Development44.88M81.61M156.5M172.97M240.28M
Selling, General & Admin32.44M49.51M59.83M71.46M80.02M
Operating Expenses77.32M131.12M60.43M72.18M320.3M
Depreciation & Amortization1.41M3.69M6.55M7.18M6.42M
EBITDA(64.09M)(107.21M)(169.4M)(164.89M)(212.18M)
EBITDA Margin-547.9%-741.3%-628.0%-467.4%-292.3%
Operating Income(65.62M)(116.65M)(189.95M)(209.87M)(247.72M)
Operating Margin-561.0%-806.6%-704.1%-595.0%-341.3%
Interest Income120K5.76M14M34.28M28.46M
Interest Expense2.98M3.34M3.26M1.73M206K
Other Income / Expenses(2.86M)2.41M10.74M36.08M28.91M
Income Before Tax(68.48M)(114.24M)(179.21M)(173.8M)(218.81M)
Pre-Tax Margin-585.5%-789.9%-664.3%-492.7%-301.4%
Income Tax Expense(1.66M)(1.52M)1.46M(4.77M)152K
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Net Margin-571.2%-779.3%-669.7%-479.2%-301.7%
EPS (Basic)(2.67)(3.80)(5.08)(2.91)(3.16)
EPS (Diluted)(2.67)(3.80)(5.08)(2.90)(3.16)
Weighted Avg Shares25.06M29.66M35.59M58.21M69.28M
Weighted Avg Shares (Diluted)25.06M29.66M35.59M58.21M69.28M

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.